Obesity and its cardiovascular effects

Diabetes/Metabolism Research and Reviews

Volumn 35, Issue 4, 2019, Pages

  Ortega Loubon, Christian ^a   Fernández Molina, Manuel ^b   Singh, Gauri ^c   Correa, Ricardo ^d  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

adipose tissue; cardiovascular disease; inflammation; obesity

Indexed keywords

ADIPOCYTOKINE; CYTOKINE; FATTY ACID; GLUCOSE; LIPID;

ADIPOSE TISSUE; ALL CAUSE MORTALITY; BODY WEIGHT; BODY WEIGHT LOSS; CARDIAC MUSCLE CELL; CARDIOVASCULAR EFFECT; DIASTOLIC DYSFUNCTION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE METABOLISM; HUMAN; HYPERTROPHY; INSULIN RESISTANCE; LEAN TISSUE; LIFESTYLE MODIFICATION; LIPOTOXICITY; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; CARDIOVASCULAR DISEASE; COMPLICATION; PATHOLOGY; PROGNOSIS;

CARDIOVASCULAR DISEASES; HUMANS; OBESITY; PROGNOSIS;

EID: 85064820920     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.3135     Document Type: Review

References (137)

1. Organization WH. Obesity and overweight. Fact Sheet February. February 2018;2018(2018):16.
2. Quach S, Campbell NR, McAlister FA, et al. Blood pressure in Canadian adults. Health Rep. 2010 Mar;21(1):37-46.
3. Piche M-E, Poirier P, Lemieux I, Despres J-P. Overview of epidemiology and contribution of obesity and body fat distribution to cardiovascular disease: an update. Prog Cardiovasc Dis. 2018 Jul - Aug;61(2):103-113.
4. Graubard BI, Orpana H, Kit BK, Flegal KM. The standard body mass index categories and the association of all-cause mortality with overweight and obesity: a systematic review and meta-analysis. JAMA. 2013 Jan 2;309(1):71-82.
5. Neubauer S, Lewis AJ, Rider OJ. The myocardium and the aorta being affected by the structural and metabolic effects of obesity. Obes Facts. 2014 Oct 23;7(5):329-338.
6. Kotowicz MA, Brennan SL, Nicholson GC, Pasco JA. The body mass index and fat as related to obesity occurrence: population-based cross-sectional data. PLoS ONE. 2012;7(1):e29580.
7. Pitcher A, Francis JM, Lewandowski A, et al. Left ventricular remodeling in obesity gender-specific differences: insights from cardiovascular magnetic resonance imaging. Eur Heart J. 2013 Jan;34(4):292-299.
8. Devereux RB, Dahlof B, de Simone G, Cramariuc D, Wachtell K, Gerdts E. Hypertensive patients with left ventricular hypertrophy and impact of left ventricular geometry on prognosis (the LIFE study). Eur J Echocardiogr. 2008 Nov;9(6):809-815.
9. Okada M, Oka R, Funahashi T, et al. Decrease in the number of obesity-related cardiovascular risk factors in Japanese with abdominal obesity that correlates with reduction of visceral fat (VACATION-J study). J Atheroscler Thromb. 2012;19(11):1006-1018.
10. Hu FB, Willett WC, Rimm EB, Hao T, Mozaffarian D. Long-term weight gain in women and men and changes in lifestyle and diet. N Engl J Med. 2011 Jun 23;364(25):2392-2404.
11. Ortega FB, Lavie CJ. Introduction and update on obesity and cardiovascular diseases 2018. Prog Cardiovasc Dis. 2018 Jul - Aug;61(2):87-88.
12. Burke LE, Fleisher LA, Alpert MA, et al. Severely obese patients undergoing surgery, cardiovascular evaluation and management: a science advisory from the American Heart Association. Circulation. 2009 Jul 7;120(1):86-95.
13. Waeber G, Mooser V, Paccaud F, et al. Relationship of lipids, glycemic status, liver enzymes, and inflammation with normal weight obesity. Nutr Metab Cardiovasc Dis. 2010 Nov;20(9):669-675.
14. Korinek J, Sierra-Johnson J, Somers VK, et al. Risk factor for cardiometabolic dysregulation and cardiovascular mortality in normal weight obesity. Eur Heart J. 2010 Mar;31(6):737-746.
15. Emerging Risk Factors C, Wormser D, Kaptoge S, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011 Mar 26;377(9771):1085-1095.
16. Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb. 2011;18(8):629-639.
17. Hamer M, Stamatakis E. Overweight and obese cardiac patients have better prognosis despite reporting worse perceived health and more conventional risk factors. Prev Med. 2013 Jul;57(1):12-16.
18. Cornier MA, Despres JP, Davis N, et al. Assessing adiposity: a scientific statement from the American Heart Association. Circulation. 2011 Nov 1;124(18):1996-2019.
19. Despres JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012 Sep 4;126(10):1301-1313.
20. Mathieu P, Poirier P, Pibarot P, Lemieux I, Despres JP. Visceral obesity: the link between inflammation, hypertension, and cardiovascular disease. Hypertension. 2009 Apr;53(4):577-584.
21. Elagizi A, Kachur S, Lavie CJ, et al. An overview and update on obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis. 2018 Jul - Aug;61(2):142-150.
22. Azimi A, Charlot MG, Torp-Pedersen C, et al. Moderately overweight is beneficial and severe obesity detrimental for patients with documented atherosclerotic heart disease. Heart. 2013 May;99(9):655-660.
23. Coutinho T, Goel K, Correa de Sa D, et al. Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: the role of “normal weight central obesity”. J Am Coll Cardiol. 2013 Feb 5;61(5):553-560.
24. Coutinho T, Goel K, Correa de Sa D, et al. Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data. J Am Coll Cardiol. 2011 May 10;57(19):1877-1886.
25. Lavie CJ, De Schutter A, Patel D, Artham SM, Milani RV. Body composition and coronary heart disease mortality—an obesity or a lean paradox? Mayo Clin Proc. 2011 Sep;86(9):857-864.
26. Lavie CJ, De Schutter A, Patel DA, Romero-Corral A, Artham SM, Milani RV. Body composition and survival in stable coronary heart disease: impact of lean mass index and body fat in the “obesity paradox”. J Am Coll Cardiol. 2012 Oct 9;60(15):1374-1380.
27. Lavie CJ, Milani RV, Artham SM, Patel DA, Ventura HO. The obesity paradox, weight loss, and coronary disease. Am J Med. 2009 Dec;122(12):1106-1114.
28. McAuley PA, Artero EG, Sui X, et al. The obesity paradox, cardiorespiratory fitness, and coronary heart disease. Mayo Clin Proc. 2012 May;87(5):443-451.
29. Clark AL, Chyu J, Horwich TB. The obesity paradox in men versus women with systolic heart failure. Am J Cardiol. 2012 Jul 1;110(1):77-82.
30. Horwich TB, Fonarow GC, Clark AL. Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis. 2018 Jul - Aug;61(2):151-156.
31. Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 2013 Apr;1(2):93-102.
32. Lavie CJ, De Schutter A, Alpert MA, Mehra MR, Milani RV, Ventura HO. Obesity paradox, cachexia, frailty, and heart failure. Heart Fail Clin. 2014 Apr;10(2):319-326.
33. Mehra MR. Fat, cachexia, and the right ventricle in heart failure: a web of complicity. J Am Coll Cardiol. 2013 Oct 29;62(18):1671-1673.
34. Melenovsky V, Kotrc M, Borlaug BA, et al. Relationships between right ventricular function, body composition, and prognosis in advanced heart failure. J Am Coll Cardiol. 2013 Oct 29;62(18):1660-1670.
35. Lavie CJ, Milani RV, Ventura HO. Effects of obesity and weight changes on cardiac and vascular structure and function. JACC Heart Fail. 2014 Oct;2(5):509-511.
36. Lavie CJ, Ventura HO. Analyzing the weight of evidence on the obesity paradox and heart failure—is there a limit to the madness? Congest Heart Fail. 2013 Jul-Aug;19(4):158-159.
37. Nagarajan V, Cauthen CA, Starling RC, Tang WHW. Prognosis of morbid obesity patients with advanced heart failure. Congest Heart Fail. 2013 Jul-Aug;19(4):160-164.
38. Writing Committee M, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013 Oct 15;128(16):e240-e327.
39. Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment—a position paper of the Obesity Society and The American Society of Hypertension. Obesity (Silver Spring). 2013 Jan;21(1):8-24.
40. Aghamohammadzadeh R, Heagerty AM. Obesity-related hypertension: epidemiology, pathophysiology, treatments, and the contribution of perivascular adipose tissue. Ann Med. 2012 Jun;44(Sup1):S74-S84.
41. da Silva AA, Do Carmo J, Dubinion J, Hall JE. The role of the sympathetic nervous system in obesity-related hypertension. Curr Hypertens Rep. 2009;11(3):206-211.
42. Lambert GW, Straznicky NE, Lambert EA, Dixon JB, Schlaich MP. Sympathetic nervous activation in obesity and the metabolic syndrome—causes, consequences and therapeutic implications. Pharmacol Ther. 2010 May;126(2):159-172.
43. Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res. 2010 May;33(5):386-393.
44. Zhang G, Yin X, Qi Y, et al. Ghrelin and cardiovascular diseases. Curr Cardiol Rev. 2010 Feb;6(1):62-70.
45. Kang YS. Obesity associated hypertension: new insights into mechanism. Electrolyte Blood Press. 2013 Dec;11(2):46-52.
46. Lee DE, Kehlenbrink S, Lee H, Hawkins M, Yudkin JS. Getting the message across: mechanisms of physiological cross talk by adipose tissue. Am J Physiol Endocrinol Metab. 2009 Jun;296(6):E1210-E1229.
47. Meijer RI, Serne EH, Smulders YM, van Hinsbergh VWM, Yudkin JS, Eringa EC. Perivascular adipose tissue and its role in type 2 diabetes and cardiovascular disease. Curr Diab Rep. 2011 Jun;11(3):211-217.
48. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest. 2008 Sep;118(9):2992-3002.
49. van Eijk IC, Peters MJ, Serne EH, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumor necrosis factor alpha blockade. Ann Rheum Dis. 2009 Mar;68(3):362-366.
50. Yasue S, Masuzaki H, Okada S, et al. Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: impact of nutritional status and adipocyte hypertrophy. Am J Hypertens. 2010 Apr;23(4):425-431.
51. Bogaert YE, Linas S. The role of obesity in the pathogenesis of hypertension. Nat Clin Pract Nephrol. 2009 Feb;5(2):101-111.
52. Bomback AS, Klemmer PJ. Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review. Am J Nephrol. 2009;30(2):140-146.
53. Goodfriend TL. Obesity, sleep apnea, aldosterone, and hypertension. Curr Hypertens Rep. 2008 Jun;10(3):222-226.
54. Lastra G, Sowers JR. Obesity and cardiovascular disease: role of adipose tissue, inflammation, and the renin-angiotensin-aldosterone system. Horm Mol Biol Clin Invest. 2013 Sep;15(2):49-57.
55. Sarzani R, Salvi F, Dessi-Fulgheri P, Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens. 2008 May;26(5):831-843.
56. Thatcher S, Yiannikouris F, Gupte M, Cassis L. The adipose renin-angiotensin system: role in cardiovascular disease. Mol Cell Endocrinol. 2009;302(2):111-117.
57. Kunes J, Kadlecova M, Vaneckova I, Zicha J. Critical developmental periods in the pathogenesis of hypertension. Physiol Res. 2012;61(1):S9-S17.
58. Kunes J, Zicha J. The interaction of genetic and environmental factors in the etiology of hypertension. Physiol Res. 2009;58(2):S33-S41.
59. Vaneckova I, Maletinska L, Behuliak M, Nagelova V, Zicha J, Kunes J. Obesity-related hypertension: possible pathophysiological mechanisms. J Endocrinol. 2014 Dec;223(3):R63-R78.
60. Rider OJ, Holloway CJ, Emmanuel Y, Bloch E, Clarke K, Neubauer S. Increasing plasma free fatty acids in healthy subjects induces aortic distensibility changes seen in obesity. Circ Cardiovasc Imaging. 2012 May 1;5(3):367-375.
61. Rider OJ, Cox P, Tyler D, Clarke K, Neubauer S. Myocardial substrate metabolism in obesity. Int J Obes (Lond). 2013 Jul;37(7):972-979.
62. Rider OJ, Francis JM, Ali MK, et al. Effects of catecholamine stress on diastolic function and myocardial energetics in obesity. Circulation. 2012 Mar 27;125(12):1511-1519.
63. Rider OJ, Francis JM, Ali MK, et al. Beneficial cardiovascular effects of bariatric surgical and dietary weight loss in obesity. J Am Coll Cardiol. 2009 Aug 18;54(8):718-726.
64. Pagano C, Calcagno A, Granzotto M, et al. Heart lipid accumulation in obese non-diabetic rats: effect of weight loss. Nutr Metab Cardiovasc Dis. 2008 Mar;18(3):189-197.
65. Alpert MA, Lavie CJ, Agrawal H, Aggarwal KB, Kumar SA. Obesity and heart failure: epidemiology, pathophysiology, clinical manifestations, and management. Transl Res. 2014 Oct;164(4):345-356.
66. Alpert MA, Omran J, Mehra A, Ardhanari S. Impact of obesity and weight loss on cardiac performance and morphology in adults. Prog Cardiovasc Dis. 2014 Jan-Feb;56(4):391-400.
67. Guerra F, Mancinelli L, Angelini L, et al. The association of left ventricular hypertrophy with metabolic syndrome is dependent on body mass index in hypertensive overweight or obese patients. PLoS ONE. 2011 Jan 31;6(1):e16630.
68. Stewart MH, Lavie CJ, Shah S, et al. Prognostic implications of left ventricular hypertrophy. Prog Cardiovasc Dis. 2018 Nov - Dec;61(5-6):446-455.
69. Horwich TB, Fonarow GC. Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J Am Coll Cardiol. 2010 Jan 26;55(4):283-293.
70. Niemann B, Chen Y, Teschner M, Li L, Silber RE, Rohrbach S. Obesity induces signs of premature cardiac aging in younger patients: the role of mitochondria. J Am Coll Cardiol. 2011 Feb 1;57(5):577-585.
71. Lavie CJ, Deedwania P, Ortega FB. Obesity is rarely healthy. Lancet Diabetes Endocrinol. 2018;6(9):678-679.
72. Neeland IJ, Gupta S, Ayers CR, et al. Relation of regional fat distribution to left ventricular structure and function. Circ Cardiovasc Imaging. 2013 Sep;6(5):800-807.
73. Rider OJ, Francis JM, Ali MK, et al. Determinants of left ventricular mass in obesity; a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2009 Apr 24;11(1):9.
74. Turkbey EB, McClelland RL, Kronmal RA, et al. The impact of obesity on the left ventricle: the multi-ethnic study of atherosclerosis (MESA). JACC Cardiovasc Imaging. 2010 Mar;3(3):266-274.
75. Rider OJ, Petersen SE, Francis JM, et al. Ventricular hypertrophy and cavity dilatation in relation to body mass index in women with uncomplicated obesity. Heart. 2011 Feb;97(3):203-208.
76. Abe Y, Ono K, Kawamura T, et al. Leptin induces elongation of cardiac myocytes and causes eccentric left ventricular dilatation with compensation. Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2387-H2396.
77. Zhang K, Chen J, Liu Y, et al. Diastolic blood pressure reduction contributes more to the regression of left ventricular hypertrophy: a meta-analysis of randomized controlled trials. J Hum Hypertens. 2013 Nov;27(11):698-706.
78. Jordan J, Yumuk V, Schlaich M, et al. A joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens. 2012 Jun;30(6):1047-1055.
79. Ruster C, Wolf G. The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. Semin Nephrol. 2013 Jan;33(1):44-53.
80. Yasue S, Ebihara K, Nakao K. Adipose tissue renin-angiotensin system in obese. Nihon Rinsho. 2012 Sep;70(9):1550-1555.
81. Marinik EL, Frisard MI, Hulver MW, et al. Angiotensin II receptor blockade and insulin sensitivity in overweight and obese adults with elevated blood pressure. Ther Adv Cardiovasc Dis. 2013 Feb;7(1):11-20.
82. Rider OJ, Francis JM, Tyler D, Byrne J, Clarke K, Neubauer S. Effects of weight loss on myocardial energetics and diastolic function in obesity. Int J Cardiovasc Imaging. 2013 Jun;29(5):1043-1050.
83. Cil H, Bulur S, Turker Y, et al. Impact of body mass index on left ventricular diastolic dysfunction. Echocardiography. 2012 Jul;29(6):647-651.
84. Russo C, Jin Z, Homma S, et al. Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. J Am Coll Cardiol. 2011 Mar 22;57(12):1368-1374.
85. Shimabukuro M, Hirata Y, Tabata M, et al. Epicardial adipose tissue volume and adipocytokine imbalance are strongly linked to human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2013 May;33(5):1077-1084.
86. Quercioli A, Pataky Z, Montecucco F, et al. Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with endocannabinoids, leptin, and inflammation. JACC Cardiovasc Imaging. 2012 Aug;5(8):805-815.
87. Oka T, Komuro I. Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure. Circ J. 2008;72(SupplementA):13-16.
88. Campbell DJ, Somaratne JB, Prior DL, et al. Obesity is associated with lower coronary microvascular density. PLoS ONE. 2013;8(11):e81798.
89. Campbell DJ, Somaratne JB, Jenkins AJ, et al. Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction. Int J Cardiol. 2013 Aug 10;167(3):1027-1037.
90. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009 May 26;53(21):1925-1932.
91. Sturm W, Sandhofer A, Engl J, et al. Influence of visceral obesity and liver fat on vascular structure and function in obese subjects. Obesity (Silver Spring). 2009 Sep;17(9):1783-1788.
92. Bucerius J, Duivenvoorden R, Mani V, et al. Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. JACC Cardiovasc Imaging. 2011 Nov;4(11):1195-1205.
93. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009 Jun;6(6):399-409.
94. Rutkowski JM, Davis KE, Scherer PE. Mechanisms of obesity and related pathologies: the macro- and microcirculation of adipose tissue. FEBS J. 2009 Oct;276(20):5738-5746.
95. Van de Voorde J, Pauwels B, Boydens C, Decaluwe K. Adipocytokines in relation to cardiovascular disease. Metabolism. 2013 Nov;62(11):1513-1521.
96. Pasarica M, Sereda OR, Redman LM, et al. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes. 2009 Mar;58(3):718-725.
97. Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br J Nutr. 2008 Aug;100(2):227-235.
98. Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013 Jan;93(1):359-404.
99. Schaffler A, Scholmerich J. Innate immunity and adipose tissue biology. Trends Immunol. 2010 Jun;31(6):228-235.
100. Northcott JM, Yeganeh A, Taylor CG, Zahradka P, Wigle JT. Adipokines and the cardiovascular system: mechanisms mediating health and disease. Can J Physiol Pharmacol. 2012 Aug;90(8):1029-1059.
101. Villarreal-Molina MT, Antuna-Puente B. Adiponectin: anti-inflammatory and cardioprotective effects. Biochimie. 2012 Oct;94(10):2143-2149.
102. Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med. 2009 Jan;6(1):27-35.
103. Yin WH, Wei J, Huang WP, Chen JW, Young MS, Lin SJ. Prognostic value of circulating adipokine levels and expressions of adipokines in the myocardium of patients with chronic heart failure. Circ J. 2012;76(9):2139-2147.
104. Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med. 2010 Jul;20(5):143-148.
105. Bertrand OF, Poirier P, Rodes-Cabau J, et al. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: a randomized placebo-controlled clinical trial. Atherosclerosis. 2010 Aug;211(2):565-573.
106. Chen X, Yang L, Zhai SD. Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies. Chin Med J (Engl). 2012;125(23):4301-4306.
107. Group BDS, Frye RL, August P, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009 Jun 11;360(24):2503-2515.
108. Franklin BA, Lavie CJ, Squires RW, Milani RV. Exercise-based cardiac rehabilitation and improvements in cardiorespiratory fitness: implications regarding patient benefit. Mayo Clin Proc. 2013 May;88(5):431-437.
109. Kaminsky LA, Arena R, Beckie TM, et al. The importance of cardiorespiratory fitness in the United States: the need for a national registry: a policy statement from the American Heart Association. Circulation. 2013 Feb 5;127(5):652-662.
110. Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA. 2009 May 20;301(19):2024-2035.
111. Lee DC, Sui X, Ortega FB, et al. Comparisons of leisure-time physical activity and cardiorespiratory fitness as predictors of all-cause mortality in men and women. Br J Sports Med. 2011 May;45(6):504-510.
112. Martin BJ, Arena R, Haykowsky M, et al. Cardiovascular fitness and mortality after contemporary cardiac rehabilitation. Mayo Clin Proc. 2013 May;88(5):455-463.
113. Akers JD, Estabrooks PA, Davy BM. Translational research: bridging the gap between long-term weight loss maintenance, research and practice. J Am Diet Assoc. 2010 Oct;110(10):1511.e3-1522.e3.
114. Borys JM, Le Bodo Y, Jebb SA, et al. EPODE approach for childhood obesity prevention: methods, progress and international development. Obes Rev. 2012 Apr;13(4):299-315.
115. Christie D, Hudson L, Mathiot A, et al. Assessing the efficacy of the Healthy Eating and Lifestyle Programme (HELP) compared with the enhanced standard care of the obese adolescent in the community: study protocol for a randomized controlled trial. Trials. 2011 Nov 16;12(1):242.
116. Sobko T, Svensson V, Ek A, et al. A randomized controlled trial for overweight and obese parents to prevent childhood obesity—early STOPP (Stockholm Obesity Prevention Program). BMC Public Health. 2011 May 18;11(1):336.
117. Taylor BJ, Heath ALM, Galland BC, et al. Prevention of Overweight in Infancy (POI.nz) study: a randomised controlled trial of sleep, food and activity interventions for preventing overweight from birth. BMC Public Health. 2011 Dec 19;11(1):942.
118. Zhai F, Wang H, Wang Z, Popkin BM, Chen C. Closing the energy gap to prevent weight gain in China. Obes Rev. 2008 Mar;9(Suppl 1):107-112.
119. Greaves CJ, Sheppard KE, Abraham C, et al. Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. BMC Public Health. 2011 Feb 18;11(1):119.
120. Simpson SA, Shaw C, McNamara R. What is the most effective way to maintain weight loss in adults? BMJ. 2011 Dec 28;343(dec28 1):d8042.
121. Van Dorsten B, Lindley EM. Cognitive and behavioral approaches in the treatment of obesity. Med Clin North Am. 2011 Sep;95(5):971-988.
122. Lavie CJ, McAuley PA, Church TS, Milani RV, Blair SN. Obesity and cardiovascular diseases. J Am Coll Cardiol. 2014 Apr 15;63(14):1345-1354.
123. Lavie CJ, Laddu D, Arena R, Ortega FB, Alpert MA, Kushner RF. Healthy weight and obesity prevention. JACC. 2018 Sept 25;72(13):1506-1531.
124. Ades PA, Savage PD, Toth MJ, et al. High-calorie-expenditure exercise: a new approach to cardiac rehabilitation for overweight coronary patients. Circulation. 2009 May 26;119(20):2671-2678.
125. Balady GJ, Arena R, Sietsema K, et al. Clinician's guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation. 2010 Jul 13;122(2):191-225.
126. Lavie CJ, Berra K, Arena R. Formal cardiac rehabilitation and exercise training programs in heart failure. J Cardiopulm Rehabil Prev. 2013 Jul-Aug;33(4):209-211.
127. Kennedy AB, Lavie CJ, Blair SN. Fitness or fatness: which is more important? JAMA. 2018 Jan 16;319(3):231-232.
128. Utz W, Engeli S, Haufe S, et al. Moderate dietary weight loss reduces myocardial steatosis in obese and overweight women. Int J Cardiol. 2013 Aug 10;167(3):905-909.
129. Bakermans AJ, Geraedts TR, van Weeghel M, et al. Fasting-induced myocardial lipid accumulation in long-chain acyl-CoA dehydrogenase knockout mice is accompanied by an impaired left ventricular function. Circ Cardiovasc Imaging. 2011 Sep;4(5):558-565.
130. Look AHEAD Research Group, Wing RR, Bolin P, et al. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. N Engl J Med. 2013 Jul 11;369(2):145-154. [published correction appears in N Engl J Med. 2014;370(19):1866]
131. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2018 Jun 21;378(25):e34.
132. Look AHEAD Research Group, Gregg EW, Jakicik JM, Blackburn G, Bloomquist P, Bray GA. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomized clinical trial. Lancet Diabetes Endocrinol. 2016 Aug 30;4(11):913-921.
133. Belalcazar LM, Ballantyne CM. Looking Back at Look AHEAD through the lens of recent diabetes outcome trials. Circulation. 2017 Feb 21;135(8):720-723.
134. Lee DC, Sui X, Artero EG, et al. Long-term effects of changes in cardiorespiratory fitness and body mass index on all-cause and cardiovascular disease mortality in men: the aerobics center longitudinal study. Circulation. 2011 Dec 6;124(23):2483-2490.
135. McAuley PA, Kokkinos PF, Oliveira RB, Emerson BT, Myers JN. Obesity paradox and cardiorespiratory fitness in 12,417 male veterans aged 40 to 70 years. Mayo Clin Proc. 2010 Feb;85(2):115-121.
136. Lavie CJ, Cahalin LP, Chase P, et al. Impact of cardiorespiratory fitness on the obesity paradox in patients with heart failure. Mayo Clin Proc. 2013 Mar;88(3):251-258.
137. Lavie CJ, De Schutter A, Patel DA, Milani RV. Does fitness completely explain the obesity paradox? Am Heart J. 2013 Jul;166(1):1-3.